Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and admin

Change in fair value of acquisition consideration

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Twist Bioscience Corp

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Twist Bioscience Corp meets Q1 expectations, eyes growth opportunities

Twist Bioscience Corp's Q1 performance met or exceeded expectations across key revenue segments, with a focus on expanding customer base and improving turnaround times.
While facing challenges such as COVID impact on China sales and margin dips due to fixed costs, the company aims for revenue growth and improved margins through strategic execution.
The company's strengths lie in strong gross margins, record bookings in NGS, and efforts towards DNA data storage alliances, positioning for future growth and innovation.
Opportunities include continued customer expansion, Fast Gene market development, and revenue growth driven by NGS and SynBio performance, amidst a value-based pricing strategy.

Twist Bioscience Corp achieves $60.2M revenue in Q2 2023

Twist Bioscience Corp's Q2 2023 earnings call highlighted strong revenue growth, cost reduction efforts, and a focus on achieving profitability. The company is navigating challenges in the biopharma sector while leveraging strengths in technology and sales execution for future growth.

Twist Bioscience Corp reports record Q3 revenue, focuses on growth

Twist Bioscience Corp delivered a strong performance in Q3, with record revenue and strategic product launches driving growth across key segments.
While facing challenges in biopharma revenue and commercial execution, the company is focused on expansion, talent acquisition, and cost management to drive future growth.
With a clear focus on innovation, market expansion, and achieving profitability milestones, Twist Bioscience Corp is well-positioned for future success and market leadership.
The company's strengths in SynBio products, strategic market positioning, and stable funding outlook underscore its potential for sustained growth and value creation.

Twist Bioscience Corp reports robust revenue growth and eyes profitability

Twist Bioscience Corp's Q4 2023 earnings call highlighted strong revenue growth, operational efficiency, and a solid financial position.
The company faces challenges in managing expenses and achieving profitability but sees opportunities in revenue growth and market expansion.
By leveraging strengths in product launches, customer relationships, and revenue growth, Twist Bioscience aims for continued success and margin expansion in fiscal 2024.

Twist Bioscience Corp excels in Q1 2024, focuses on growth

Twist Bioscience Corp's Q1 2024 earnings call highlighted robust revenue growth, margin expansion, and strategic focus on operational efficiency. The company's emphasis on customer needs, premium pricing, and cost efficiency positions it well for future growth and profitability.

Twist Bioscience reports robust Q2 revenue growth and margin targets

Twist Bioscience Corp delivered strong revenue growth and aims for margin improvement, driven by successful product lines and strategic initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to leverage market opportunities and regulatory advantages.
With a focus on innovation, market expansion, and margin growth, Twist is poised for continued success and competitive growth in the biopharma sector.
Navigating operational challenges and seizing growth opportunities will be crucial for Twist Bioscience to achieve its financial targets and sustain market leadership.

Twist Bioscience Corp reports robust Q3 revenue growth and profitability outlook

Twist Bioscience Corp delivered strong revenue growth and operational performance in Q3 2024, driven by robust NGS and biopharma revenue streams.
While facing challenges in achieving profitability targets, the company's focus on margin improvement and capacity expansion positions it for future growth.
Guidance for fiscal 2024 indicates promising revenue growth, highlighting opportunities for sustained expansion and enhanced financial performance.

Twist Bioscience Corp reports record revenue and aims for profitability

Twist Bioscience Corp delivered strong financial performance, with record revenue and margin growth driven by key product segments and operational efficiencies.
The company's focus on achieving adjusted EBITDA profitability and cash flow positivity, along with robust fiscal 2025 guidance, signals a path towards sustainable growth.
While challenges like cost management and market competition persist, opportunities in market traction, revenue diversification, and innovation position the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by Sosei Heptares. The

Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies Against GPCR Targets

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that synthetic RNA positive controls are now available for the SARS-CoV-2 Omicron (B.1.1.529/BA.1) variants first identified in South Africa. Since the initial discovery, the variant has been identified and is spreading quickly worldwide, with more than 50 countries confir

Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests

The stock price of Twist Bioscience Corp (NASDAQ: TWST) increased by 10.38% today. This is why it happened.

Twist Bioscience Stock (TWST): Why The Price Jumped Today

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of synthetic DNA using its silicon platform, today announced the launch of the Twist cfDNA Pan-cancer Reference Standards, a high-quality standardized control for use in the development and continuous monitoring of liquid biopsy tests to detect cancer from blood samples. Liquid biopsy tests, which rely on NGS-based circulating tumor DNA (ctDNA)

Twist Bioscience Launches Circulating Tumor DNA Reference Controls for Development of Liquid Biopsy Assays

Global-e Online Ltd

Veeva Systems

Analyst estimates suggest the stock market isn't giving these stocks the attention they deserve.

3 High-Growth Stocks Wall Street Thinks Could Soar 30% or More

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development, data storage, will participate in the virtual SRC-SIA Webinar on the Decadal Plan for Semiconductors held on December 9, 2021 from 12:30pm to 2:00pm (EST). The webinar aims to identify a compelling researc

Twist Bioscience Announces Participation in SRC-SIA Webinar on the Decadal Plan for Semiconductors

On Monday, Twist Bioscience Corp (NASDAQ:TWST) shares declined by more than 8% after announcing its fiscal fourth-quarter results. The company reported its most recent quarterly results before markets opened, missing the consensus analyst expectation on earnings per share.

Twist Bioscience stock prediction after plunging 8% on earnings miss

Twist Bioscience Corporation (NASDAQ: TWST) reported a 17% Y/Y increase in its Q4 revenues to $37.95 million, beating the Wall Street estimate of $37.02 million, driven by strength in SynBio, NGS, biopharma businesses. The Company shipped products to approximately 2,900 customers in fiscal 2021, versus about 2,200 in fiscal 2020.

Why Are Twist Bioscience Shares Plunging Today?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2021 ended September 30, 2021. “Fiscal 2021 was a transformational year for Twist, as we delivered significant revenue growth by diversifying and expanding our customer base in synbio and

Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it entered into a definitive agreement to acquire Abveris, (formally known as AbX Biologics, Inc.) a privately held in vivo antibody discovery services company developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global

Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities

SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Invetx, a pioneer in protein-based therapeutics for animal health, today announced an extension to their existing antibody therapeutic partnership. The extended agreement covers the addition of next-generation synthetic antibody phage display technology for the discovery of n

Twist Bioscience Expands Partnership with Invetx to Include Discovery of Best-in-Class Antibodies to Treat Multiple Diseases in Cats and Dogs

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Twist Bioscience (TWST) Q4 Earnings Expected to Decline

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has launched Revelar Biotherapeutics, Inc., an independently operated, new biotechnology company to develop and commercialize an antibody, discovered and optimized by Twist Biopharma, a division of Twist Bioscience, that neutralizes all known variants of concern of the

Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15 at 3:20 p.m. Eastern Time. The presentation will be webcast live and can be accessed by visiting the “Investor Calend

Twist Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has been included in Inc.'s first annual Best-Led Companies list, an exciting 12-point measure of management excellence across the middle market — a select, data-driven list of the very strongest U.S. firms with revenue of $50 million to $2 billion. “I am thrilled

Twist Bioscience Named in Inc.'s First Annual Best-Led Companies List

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2021 fourth quarter and full year ended September 30, 2021, before the opening of the market on Monday, November 22, 2021. The company plans to hold a conference call and live audio webcast for analysts and investors

Twist Bioscience to Report Fiscal 2021 Fourth Quarter and Full Year Financial Results on Monday, November 22, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of its Exome 2.0, featuring the most comprehensive coverage of protein-coding and noncoding regions of the genome, as well as best-in-class performance to reduce downstream sequencing costs. “We have been working with Twist for the last three years and recently

Twist Bioscience Launches Exome 2.0 for Genomics Research

Vertex Pharmaceuticals

Both are biotech stocks with tremendous long-term opportunities.

2 Stocks You'll Probably Never Want to Sell

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an agreement with the Broad Institute for the distribution of a customized next-generation sequencing (NGS) target enrichment exome panel designed for the identification and research of a wide range of cancer, rare and inherited disease genes from patient samples. Twist wi

Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research

SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Steffen Hellmold to the newly created position of senior vice president, business development, data storage. “We have made significant technological advances in our DNA data storage division and are now focused on laying the foundation for commercialization of this di

Twist Bioscience Appoints Steffen Hellmold as Senior Vice President, Business Development, Data Storage

Coinbase

Unity Software

It's time to follow the money in three Cathie Wood stocks, while sticking to the price charts in order to enjoy smarter money investments. The post 3 IPO Cathie Wood Stocks to Buy appeared first on InvestorPlace.

3 IPO Cathie Wood Stocks to Buy

Centogene NV (NASDAQ: CNTG) and Twist Bioscience Corporation (NASDAQ: TWST) have signed a contract to develop and commercialize custom assay kits for rare diseases. The financial details of the deal were not disclosed.

Centogene, Twist Join Forces For Custom Test Kits For Rare Diseases

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that they have signed a contract to collaborate on the development and commercialization of custom assay kits for rare

Twist Bioscience and CENTOGENE to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

Twist Bioscience is a synthetic biology company that is able to produce DNA at significantly lower costs than competitors.

Twist Stock: Manufacturing The Future

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an expansion of its expert-led Alliance Panel product offering. Designed through collaboration with world-leading experts, Twist Alliance Panels combine validated content with Twist next-generation sequencing (NGS) workflow, target enrichment and DNA probes. In an extensio

News for Twist Bioscience Corp Stock (TWST)